Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Lack of concordance between residual viremia and viral variants driving de novo infection of CD4(+) T cells on ART.

Puertas MC, Noguera-Julian M, Massanella M, Pou C, Buzon MJ, Clotet B, Stevenson M, Paredes R, Blanco J, Martinez-Picado J.

Retrovirology. 2016 Aug 2;13(1):51. doi: 10.1186/s12977-016-0282-9.

2.

Immunological and pharmacological strategies to reactivate HIV-1 from latently infected cells: a possibility for HIV-1 paediatric patients?

Martínez-Bonet M, Clemente MI, Serramía MJ, Moreno S, Muñoz E, Muñoz-Fernández MA.

J Virus Erad. 2015 Jul 1;1(3):148-52. Review.

3.

The Latent Reservoir for HIV-1: How Immunologic Memory and Clonal Expansion Contribute to HIV-1 Persistence.

Murray AJ, Kwon KJ, Farber DL, Siliciano RF.

J Immunol. 2016 Jul 15;197(2):407-17. doi: 10.4049/jimmunol.1600343. Review.

PMID:
27382129
4.

Persistent HIV-1 replication maintains the tissue reservoir during therapy.

Lorenzo-Redondo R, Fryer HR, Bedford T, Kim EY, Archer J, Kosakovsky Pond SL, Chung YS, Penugonda S, Chipman JG, Fletcher CV, Schacker TW, Malim MH, Rambaut A, Haase AT, McLean AR, Wolinsky SM.

Nature. 2016 Feb 4;530(7588):51-6. doi: 10.1038/nature16933. Epub 2016 Jan 27.

5.

Establishment and Replenishment of the Viral Reservoir in Perinatally HIV-1-infected Children Initiating Very Early Antiretroviral Therapy.

Martínez-Bonet M, Puertas MC, Fortuny C, Ouchi D, Mellado MJ, Rojo P, Noguera-Julian A, Muñoz-Fernández MA, Martinez-Picado J.

Clin Infect Dis. 2015 Oct 1;61(7):1169-78. doi: 10.1093/cid/civ456. Epub 2015 Jun 10.

6.

Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor.

Wolstein O, Boyd M, Millington M, Impey H, Boyer J, Howe A, Delebecque F, Cornetta K, Rothe M, Baum C, Nicolson T, Koldej R, Zhang J, Keech N, Camba Colón J, Breton L, Bartlett J, An DS, Chen IS, Burke B, Symonds GP.

Mol Ther Methods Clin Dev. 2014 Feb 12;1:11. doi: 10.1038/mtm.2013.11. eCollection 2014.

7.

Potential implication of residual viremia in patients on effective antiretroviral therapy.

Sahu GK.

AIDS Res Hum Retroviruses. 2015 Jan;31(1):25-35. doi: 10.1089/AID.2014.0194. Review.

8.

HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection.

Wagner TA, McLaughlin S, Garg K, Cheung CY, Larsen BB, Styrchak S, Huang HC, Edlefsen PT, Mullins JI, Frenkel LM.

Science. 2014 Aug 1;345(6196):570-3. doi: 10.1126/science.1256304. Epub 2014 Jul 10.

9.

Early initiation of combination antiretroviral therapy in HIV-1-infected newborns can achieve sustained virologic suppression with low frequency of CD4+ T cells carrying HIV in peripheral blood.

Bitnun A, Samson L, Chun TW, Kakkar F, Brophy J, Murray D, Justement S, Soudeyns H, Ostrowski M, Mujib S, Harrigan PR, Kim J, Sandstrom P, Read SE.

Clin Infect Dis. 2014 Oct;59(7):1012-9. doi: 10.1093/cid/ciu432. Epub 2014 Jun 9.

10.

Residual viremia in an RT-SHIV rhesus macaque HAART model marked by the presence of a predominant plasma clone and a lack of viral evolution.

Kauffman RC, Villalobos A, Bowen JH, Adamson L, Schinazi RF.

PLoS One. 2014 Feb 5;9(2):e88258. doi: 10.1371/journal.pone.0088258. eCollection 2014.

11.

Recent trends in HIV-1 drug resistance.

Siliciano JD, Siliciano RF.

Curr Opin Virol. 2013 Oct;3(5):487-94. doi: 10.1016/j.coviro.2013.08.007. Epub 2013 Sep 7. Review.

12.

Modelling HIV-1 2-LTR dynamics following raltegravir intensification.

Luo R, Cardozo EF, Piovoso MJ, Wu H, Buzon MJ, Martinez-Picado J, Zurakowski R.

J R Soc Interface. 2013 May 8;10(84):20130186. doi: 10.1098/rsif.2013.0186. Print 2013 Jul 6.

13.

An increasing proportion of monotypic HIV-1 DNA sequences during antiretroviral treatment suggests proliferation of HIV-infected cells.

Wagner TA, McKernan JL, Tobin NH, Tapia KA, Mullins JI, Frenkel LM.

J Virol. 2013 Feb;87(3):1770-8. doi: 10.1128/JVI.01985-12. Epub 2012 Nov 21.

14.

Redefining the viral reservoirs that prevent HIV-1 eradication.

Eisele E, Siliciano RF.

Immunity. 2012 Sep 21;37(3):377-88. doi: 10.1016/j.immuni.2012.08.010. Review.

15.

De novo generation of cells within human nurse macrophages and consequences following HIV-1 infection.

Gartner S, Liu Y, Natesan S.

PLoS One. 2012;7(7):e40139. doi: 10.1371/journal.pone.0040139. Epub 2012 Jul 18.

16.

BET bromodomain inhibition as a novel strategy for reactivation of HIV-1.

Banerjee C, Archin N, Michaels D, Belkina AC, Denis GV, Bradner J, Sebastiani P, Margolis DM, Montano M.

J Leukoc Biol. 2012 Dec;92(6):1147-54. doi: 10.1189/jlb.0312165. Epub 2012 Jul 16.

17.

HIV latency.

Siliciano RF, Greene WC.

Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007096. doi: 10.1101/cshperspect.a007096. Review.

18.

Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected.

Gutiérrez C, Díaz L, Vallejo A, Hernández-Novoa B, Abad M, Madrid N, Dahl V, Rubio R, Moreno AM, Dronda F, Casado JL, Navas E, Pérez-Elías MJ, Zamora J, Palmer S, Muñoz E, Muñoz-Fernández MÁ, Moreno S.

PLoS One. 2011;6(12):e27864. doi: 10.1371/journal.pone.0027864. Epub 2011 Dec 8.

19.

Early antiretroviral therapy in HIV-1-infected infants, 1996-2008: treatment response and duration of first-line regimens.

Judd A; European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord.

AIDS. 2011 Nov 28;25(18):2279-87. doi: 10.1097/QAD.0b013e32834d614c.

20.
Items per page

Supplemental Content

Write to the Help Desk